开元官网登录入口

Shanghai, China - The 5^th China International Import Expo (hereinafter referred to as "CIIE") was successfully held at the National Exhibition and Convention Center (NECC) in Shanghai from November 5 to 10. As a leading Chinese-developed surgical robot company, Shanghai MicroPort MedBot (Group) Co., Ltd. (hereinafter referred to as "MicroPort^® MedBot^®") showcased its flagship product – the Toumai^® Laparoscopic Surgical Robot – at the venue, manifesting the superb glitz, glamor, and strength of China’s intelligent medical robots to the exhibitors and visitors from all over the world.

In the "New Wonders" section at the Shanghai Booth during the exhibition named "10 Years of the New Era", innovative results of Shanghai’s three leading industries – integrated circuits, biomedicine, and artificial intelligence – were on display. The eye-catching Toumai^® Laparoscopic Surgical Robot, as the first Chinese-developed four-arm laparoscopic robot approved by the National Medical Products Administration (NMPA) for marketing, beckoned various visitors to stop by and take a closer look.

The Toumai^® Laparoscopic Surgical Robot is composed of the Surgeon Console, the Patient Cart, and the Vision Cart, and adopts the client-server remote operation technology. The surgeon sits at the Surgeon Console, controls the instruments on the Patient Cart via the master manipulator based on the three-dimensional images in sight, thereby enabling the instruments to move inside the patient to complete the surgery. Toumai^® boasts the clinical advantages of highly flexible wrist surgical instruments and three-dimensional realistic surgical field, thus allowing every surgeon and test driver to enjoy "immersive experience". Furthermore, its technical prowess to automatically filter out hand tremors and convert them into more precise movements enables surgeons to have high-quality vision, precision, and maneuverability.

By the end of September this year, the Toumai^® Laparoscopic Surgical Robot has completed 300 robot-assisted clinical validation surgeries in departments of urology, general surgery, gynecology, and thoracic surgery in 22 hospitals, spanning 13 provinces nationwide. It is a sign that the four-arm Toumai^® Laparoscopic Surgical Robot has become increasingly sophisticated in clinical application with its highly stable performance, thereby fully meeting the clinical requirements of surgical robots. Each surgery ensures complete safety for patients and creates immersive experience for surgeons to extend their visual scope and hand-use. What lies behind this is the excellent R&D strength of Chinese-developed laparoscopic robots and their breath-taking breakthroughs in innovation.

At the CIIE site, with the four stretching arms of Toumai^® at the MicroPort^® MedBot^® Booth, the blossoming flowers on the human body model table displayed its most beautiful posture on the Vision Cart, attracting an endless stream of visitors to look closely at the product, experience the demonstration, and get to know its technical strength. When they heard that Toumai^® has carried out the world’s longest distance 5G robotic surgery for several patients in Xinjiang, spanning 5,000 kilometers between Kizilsu Kirghiz Autonomous Prefecture of the Xinjiang Uygur Autonomous Region and Nanjing of Jiangsu Province, they were proud of Chinese intelligent surgical robots for setting such a historical record, and they also looked forward to Toumai^® performing difficult, complicated surgeries in hospitals in remote, less-developed regions.

So far, Toumai^® has created numerous "first and only" records in various fields, being the first and only four-arm laparoscopic robot independently developed and approved by a Chinese company as well as the first laparoscopic robot in Asia to win the Red Dot Award of Germany. Beyond that, Toumai^® also performed the first domestic robotic-assisted radical surgery of prostatic cancer, the first Chinese-developed robotic-assisted single-port surgery, the first Chinese-developed robotic-assisted partial nephrectomy, and the first Chinese-developed robotic-assisted radical surgery of lung cancer... Each of these records marks a milestone of the Chinese-developed laparoscopic robot in innovation to empower Chinese-developed intelligent surgical robots to reach more areas in China and the world at large.

The CIIE is now in its fifth year. As the first national exhibition under the theme of import in the international arena, it has given full play to its role of fueling worldwide procurement, investment, cultural and people-to-people exchanges, as well as openness and cooperation, establishing itself as an important gateway for China to share its opportunities with the rest of the world. The year 2022 witnessed the participation of 145 countries, regions, and international organizations. Over 280 enterprises, including those among the Fortune Global 500 and many industry leaders, made their presence at this grand event.

Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort^® MedBot^®, said at the CIIE, "As a major event on a global scale, the CIIE stands as a crucial platform for prominent companies throughout the world to share China’s development opportunities, which is of great significance for MicroPort^® MedBot^®! The enthusiasm and curiosity shown by the visitors and leaders at the CIIE for MicroPort^® MedBot^® have profoundly boosted our confidence! The road is under our footsteps that will lead us to a promising future. We will use the CIIE as a new opportunity to popularize domestic surgical robots and enable Chinese intelligent manufacturing to "go global", so that surgeons and patients from all over the world can have access to cutting-edge medical technology, thereby fulfilling the company’s founding aspiration to "Make Surgery Easier, Safer and Less Invasive".